Leqembi included in China’s commercial insurance innovative drug list December 9, 2025 00:30 Non Regulatory Read more
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment December 4, 2025 07:45 Non Regulatory Read more
New data on lecanemab to be presented at CTAD conference November 19, 2025 00:30 Non Regulatory Read more
Leqembi® approved for IV maintenance treatment in the United Kingdom November 14, 2025 00:30 Non Regulatory Read more
Invitation to presentation of BioArctic’s third quarter report for July – September 2025 on November 13 at 9.30 a.m. CET November 4, 2025 10:00 Non Regulatory Read more
Health Canada Grants Authorization for Leqembi® (lecanemab) October 27, 2025 00:35 Non Regulatory Read more
First patient treated with Leqembi® (lecanemab) in the Nordics October 14, 2025 09:05 Non Regulatory Read more
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025 October 14, 2025 07:00 Non Regulatory Read more
Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S. October 6, 2025 22:35 Non Regulatory Read more
Gunilla Osswald awarded Uppsala University Alumnus of the year 2025 September 9, 2025 09:05 Non Regulatory Read more
Invitation to presentation of BioArctic’s second quarter report for April – June 2025 on August 28 at 9.30 a.m. CET August 21, 2025 09:00 Non Regulatory Read more
Latest data presented at AAIC 2025 reinforces lecanemab’s clinical effect with consistent safety profile July 31, 2025 01:30 Non Regulatory Read more
Lecanemab four-year efficacy and safety data to be presented at AAIC 2025 July 22, 2025 08:00 Non Regulatory Read more
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association July 16, 2025 09:30 Non Regulatory Read more
Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize June 26, 2025 10:15 Non Regulatory Read more
BioArctic’s Capital Markets Day 2025 – entering a new era of growth June 2, 2025 10:30 Non Regulatory Read more
Invitation to presentation of BioArctic’s first quarter report for January – March 2025 on May 21 at 9.30 a.m. CET May 13, 2025 08:30 Non Regulatory Read more
Exidavnemab phase 2a study expanded to include MSA patients May 8, 2025 13:30 Non Regulatory Read more
MHRA to evaluate monthly intravenous maintenance dosing of Leqembi[®] for the treatment of early Alzheimer’s disease in the UK April 30, 2025 09:30 Non Regulatory Read more
BioArctic receives European substance patent for exidavnemab April 23, 2025 13:00 Non Regulatory Read more
Invitation to BioArctic’s Capital Markets Day 2025 in Stockholm March 27, 2025 10:00 Non Regulatory Read more
Latest data on lecanemab and exidavnemab to be presented at the 2025 AD/PD™ congress March 27, 2025 08:00 Non Regulatory Read more
Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University’s Innovation and Entrepreneurship Prize March 12, 2025 08:00 Non Regulatory Read more
Therapeutic Goods Administration decides not to register lecanemab in Australia March 3, 2025 09:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s fourth quarter report for October – December 2024 February 5, 2025 08:30 Non Regulatory Read more
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US January 14, 2025 01:00 Non Regulatory Read more
